Statistics

Total Visits

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone48

Select a period of time:

Number of views in the range

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone24

Views

Views
August 20241
September 20243
October 20244
November 20243
December 20249
January 20254
February 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States16
United Arab Emirates2
Finland2
United Kingdom2
Italy2
 

Top cities views

Views
London2
Helsinki2
Los Angeles1